When the Golden State Warriors left Oakland after the 2018-19 season, Stephen Curry's pregame tunnel shot ritual faded away.
35m
Positive CTX310 Phase 1 Results Might Change The Case For Investing In CRISPR Therapeutics (CRSP)
Earlier this month, CRISPR Therapeutics announced positive Phase 1 data for its investigational in vivo CRISPR/Cas9 therapy CTX310, which showed substantial and durable reductions in key lipid levels ...
Mark Boggett is CEO of the world’s first listed space tech fund, leading global space investor Seraphim Space.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback